SCHEMBL9869261

SCHEMBL9869261

Cc1ccccc1-c1nsc(S)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.43
GAA P10253 2/20 0.41
CYP1A2 P05177 5/20 0.40
CYP2C19 P33261 5/20 0.40
CYP3A4 P08684 3/20 0.40
SMN1; SMN2 Q16637 7/20 0.40
NPC1 O15118 6/20 0.40
RAB9A P51151 5/20 0.40
MAPK1 P28482 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
HSP90AA1 P07900 1/20 0.39
CYP2D6 P10635 3/20 0.38
HSD17B10 Q99714 3/20 0.38
CLK4 Q9HAZ1 2/20 0.38
ALOX15 P16050 2/20 0.38
TSHR P16473 1/20 0.38
USP2 O75604 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
MAPT P10636 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6532311 0.79 NPC1 (0.38) GAACYP1A2SMN1; SMN2NPC1RAB9A
SCHEMBL9867577 0.78 NPC1 (0.48) L3MBTL1CYP1A2CYP2C19CYP3A4SMN1; SMN2
SCHEMBL9866354 0.78 MPL (0.40) L3MBTL1GAASMN1; SMN2NPC1RAB9A
SCHEMBL9865831 0.77 ALDH1A1 (0.46) L3MBTL1GAACYP1A2CYP2C19CYP3A4
SCHEMBL9868234 0.74 L3MBTL1 (0.52) L3MBTL1GAACYP1A2CYP2C19CYP3A4
SCHEMBL9868332 0.74 PSMB8 (0.45) CYP1A2CYP2C19CYP3A4MAPK1TDP1
SCHEMBL11810775 0.73 HSP90AA1 (0.55) L3MBTL1GAACYP1A2CYP2C19CYP3A4
SCHEMBL2213825 0.72 ADORA3 (0.59) L3MBTL1SMN1; SMN2NPC1RAB9AMAPK1
SCHEMBL9868827 0.71 L3MBTL1 (0.41) L3MBTL1GAACYP1A2CYP2C19CYP3A4
SCHEMBL9867475 0.71 CA1 (0.45) L3MBTL1GAACYP1A2CYP2C19CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160221985-A1 METHOD FOR THE PREPARATION OF THIADIAZOLES BERCOT ERIC A (US) 2016-08-04 US disclosed
US-9296735-B2 Method for the preparation of thiadiazoles AMGEN INC. (US) 2016-03-29 US disclosed
US-20150141655-A1 METHOD FOR THE PREPARATION OF THIADIAZOLES AMGEN INC. 2015-05-21 US disclosed
US-4985450-A TREATMENT OF GLAUCOMA AVENTIS PHARMACEUTICALS INC. 1991-01-15 US disclosed
US-4873239-A GLAUCOMA TREATMENT HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) 1989-10-10 US disclosed
EP-0276822-A1 Arylthiadiazolylsulfonamides and derivatives, a process for their preparation and their use as medicaments HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1988-08-03 EP disclosed
US-4758578-A Arylthiadiazolylsulfonamides, pharmaceutical compositions and use HOECHST ROUSSEL PHARMACEUTICALS, INC. (US) 1988-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150141655-A1 METHOD FOR THE PREPARATION OF THIADIAZOLES GAPDH, TALDO1, HOGA1 L3MBTL1 3367/4885GAA 801/4885CYP1A2 148/4885
US-20160221985-A1 METHOD FOR THE PREPARATION OF THIADIAZOLES GAPDH, TALDO1, HOGA1 L3MBTL1 3367/4885GAA 801/4885CYP1A2 148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.